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Although Parkinson’s disease (PD) has been tradi-
tionally classified as a motor disorder, growing 
evidence recognises that several non-motor symptoms 
(NMS) are inherent to the disease, including gastro-
intestinal, neuropsychiatric, cognitive and olfactory 
disturbances. Moreover, some of these symptoms have 
been shown to be present for up to 15 years prior to the 
diagnosis of PD [1]. Practically every PD patient suffers 
from several NMS, to varying extents and with differing 
profiles, during the course of their disease.  These symp-
toms affect a broad range of physiological systems, have 
a significant impact upon patients’ quality of life and 
often require multiple pharmacological therapies. Given 
that PD is an age-related disorder, and that many of the 
NMS symptoms present at advanced disease stages, the 
patients with the greatest need of these therapies are 
elderly. Increasing polypharmacy in an aged population 
is not desirable due to the associated adverse effects. 
Thus, there is a clear and growing need for non-
pharmacological interventions that can address both the 
motor and NMS of PD.  
Physical exercise has repeatedly been demonstrated to 
alleviate comorbidities associated with aging, and to 
contribute to reducing an individual’s risk of developing 
neurodegenerative conditions such as PD or Alzhei-
mer’s disease (AD) [2]. The importance of physical 
exercise for reducing the prevalence of non-
communicable diseases has been highlighted by the 
World Health Organisation, in their 2010 publication, 
"Global Recommendations on Physical Activity for 
Health".  Moreover, evidence has accumulated to sug-
gest that exercise can ameliorate many of the symptoms 
of PD, not only the motor dysfunction, but also some of 
the NMS, such as cognitive impairment and depression 
[3]. However, in order to decipher the cellular and 
molecular mechanisms underlying the potential 
beneficial effects of exercise in PD, it is necessary to 
employ animal models. The most common models used 
by the scientific community focus on replicating the 
motor symptoms of the disease, by applying a chemical 
lesion in order to cause degeneration of the nigrostriatal 
dopaminergic pathway, which is responsible for con-
trolling movement. However, such models are not 
useful for examining the NMS, which typically involve 
several different neurotransmitter pathways and 
multiple regions of the brain.  Preclinical  studies to date 
utilising exercise as either  a  neuroprotective  or  neuro- 
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restorative intervention have reported conflicting results 
in terms of both be-havioural and molecular outputs [4]. 
A recently-developed animal model, involving induc-
tion of α-synuclein overexpression in the adult rat brain 
using adeno-associated viral (AAV) vectors, is widely 
considered to most consistently reproduce the patho-
logical features and progressive neurodegeneration 
associated with human PD [5]. However, to date there 
have been no reports on the use of this model to inter-
rogate potential effects of exercise on PD symptoms.  
In our recent study [6], we addressed this by employing 
the AAV-α-synuclein rat model to test whether exercise 
could positively impact upon the development of motor 
and/or NMS of PD. We focused on the cognitive aspect 
of NMS such as memory tasks, due to the fact that mild 
cognitive impairment in PD (PD-MCI) has been shown 
to be present in up to 43% of patients with PD [7].  
Adult male Sprague-Dawley rats were given free access 
to running wheels in cages (voluntary exercise) from 
one week after administration of AAV-α-synuclein into 
the substantia nigra. We found that voluntary exercise 
had no effect on motor function, measured by perfor-
mance on the Rotarod apparatus, or on dopaminergic 
neuronal loss in the substantia nigra. However, over-
expression of α-synuclein significantly impaired the 
ability of the animals to perform hippocampal-
associated cognitive tasks. This was associated with 
deficits in hippocampal neurogenesis, a form of neuro-
plasticity and a key cellular process underlying learning 
and memory. Importantly, voluntary exercise protected 
against this cognitive dysfunction, and this protective 
effect was mediated, at least in part, by alterations in 
neurogenesis levels.  
This is the first study to date that has employed the 
AAV-α-synuclein model to investigate exercise as a 
therapeutic intervention, and its strength lies in the fact 
that this model is widely accepted to be the most similar 
to the progressive nature of the human condition. 
Moreover, we have shown at least one mechanism that 
is involved in exercise-induced neuroprotection. 
However, it is likely that several distinct mechanisms 
are at play; further work is needed to define these 
processes and their relative contributions, in order to 
explore specific therapeutic targets for PD. It must be 
appreciated that there are difficulties associated with 
measuring the effects of exercise in patients, as well as 
in animal models, that have problems with their motor 
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function. Nevertheless, all of the available evidence 
suggests a growing rationale for including structured 
exercise programmes as part of a patient’s therapeutic 
regimen. Exercise should be incorporated into a holistic 
personalised treatment programme that is tailored to 
each patient’s specific needs and, importantly, their 
motor abilities.  
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